Systems and methods for heart block

By applying DC or high-frequency AC to the heart tissue, a reversible conduction block is generated, and the problems of long ablation time and unnecessary ablation in the prior art are solved, achieving more efficient and precise cardiac ablation.

CN111989036BActive Publication Date: 2024-12-06PRESIDIO MEDICAL INC
View PDF 13 Cites 0 Cited by

Patent Information

Application Number
CN201980023079.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-02-09
Filing Date
2019-02-08
Publication Date
2024-12-06
Estimated Expiration
2039-02-08

AI Technical Summary

Technical Problem

Existing electrophysiological cardiac ablation procedures require prolonged continuous ablation and may lead to unnecessary tissue ablation and are difficult to assess whether ablation is therapeutic.

Method used

Reversible conduction blockade is created by applying DC or high-frequency AC to the heart tissue, testing whether ablation is suitable for therapeutic ablation, preventing unnecessary ablation, and using catheter and electrode systems to deliver current to the heart tissue for reversible occlusion or Ablation.

Benefits of technology

The therapeutic properties of ablation are achieved without damaging the heart tissue, reducing ablation time and improving the accuracy and safety of ablation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111989036B_ABST
    Figure CN111989036B_ABST
Patent Text Reader

Abstract

The present disclosure relates to electrophysiological cardiac ablation devices, methods and systems. In particular, the present disclosure relates to devices, methods and systems for producing a reversible non-ablative blockade of cardiac tissue, testing cardiac tissue, and ablating cardiac tissue.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Incorporation by reference into any priority application

[0002] This application claims the benefit of 35 U.S.C. §119(e) as a non-provisional application of U.S. Provisional Application No. 62 / 628,810, filed on February 9, 2018, which is hereby incorporated by reference in its entirety. Any and all applications identified as claiming foreign or domestic priority in the Application Data Sheet filed with this application are hereby incorporated by reference in accordance with 37 CFR 1.57. Technical Field

[0003] The present disclosure relates to electrophysiological cardiac ablation devices, methods and systems. In particular, the present disclosure relates to devices, methods and systems for producing cardiac tissue blockade, testing cardiac tissue and ablating cardiac tissue. Background Art

[0004] Electrophysiology (EP) cardiac ablation procedures currently require serial ablations of cardiac tissue followed by evaluation of whether a particular ablation resulted in a change, reduction or modification of abnormal cardiac activity, including arrhythmia. This process typically takes a long time (e.g., hours) and utilizes a procedure suite, and may result in unnecessary or non-therapeutic ablation of cardiac tissue that typically does not regenerate. SUMMARY OF THE INVENTION

[0006] It is therefore desirable in some embodiments to provide devices and / or methods to allow testing of whether a particular piece of cardiac tissue is suitable for therapeutic ablation relative to iatrogenic ablation (e.g., to reversibly test whether ablation of a given tissue is indeed therapeutic before potentially permanently ablating the tissue). This can be done by applying direct current to the cardiac tissue and / or applying high frequency alternating current to produce a non-ablative reversible blockade of the cardiac tissue. Direct systems and methods can be implemented to prevent ablation after applying direct current, thereby preserving the tissue.

[0007] The methods and apparatus or devices disclosed herein each have several aspects, no single one of which is solely responsible for its desirable attributes.Without limiting the scope of the disclosure, such as by the appended claims, its more prominent features will now be discussed briefly.

[0008] In some configurations, disclosed herein are methods for performing cardiac electrophysiology studies in a patient. The method may include sensing electrical activity of a first cardiac target tissue; determining that the electrical activity of the first cardiac target tissue has a target characteristic; delivering a first non-ablative direct current to the first cardiac target tissue sufficient to produce a reversible conduction block in the first cardiac target tissue; and / or observing the presence of the target characteristic after delivering the first non-ablative direct current.

[0009] In some configurations, the target characteristic comprises abnormal electrical activity. In some configurations, the method may further include ablating the first cardiac target tissue if the target characteristic is absent after delivering the first non-ablative direct current to the first cardiac target tissue. The method may further include sensing electrical activity of the second cardiac target tissue; and determining that the electrical activity of the first cardiac target tissue has the target characteristic.

[0010] In some configurations, the method may further include delivering a second non-ablative direct current to the second cardiac target tissue sufficient to produce a reversible conduction block in the second cardiac target tissue; and observing the presence of the target feature after delivering the second non-ablative direct current.

[0011] In some configurations, the method may further include ablating the second cardiac target tissue if there is a lack of pathological arrhythmia after delivering the second non-ablative direct current to the second cardiac target tissue.

[0012] In some configurations, the first non-ablative direct current can include a cathodic direct current and an anodic direct current, wherein the cathodic direct current and the anodic direct current cycle.

[0013] In some configurations, the first non-ablative direct current comprises a frequency of less than about 1 Hz, 0.5 Hz, 0.1 Hz, 0.05 Hz, 0.01 Hz, about 0.01 Hz to 1 Hz, and a range including any two of the foregoing values.

[0014] In some configurations, the first non-ablative direct current has an amplitude of less than approximately 100 mA, 50 mA, 20 mA, 10 mA, 5 mA, 1 mA, or less, or a range including any two of the foregoing values.

[0015] In some configurations, the first cardiac target tissue includes myocardium, endocardium, or epicardium. The first cardiac target tissue may include left atrial tissue and / or right atrial tissue; and / or left ventricular tissue and / or right ventricular tissue. The first cardiac target tissue may also include pulmonary artery tissue or venous tissue.

[0016] In some configurations, the methods are used to treat cardiac arrhythmias, including but not limited to atrial fibrillation, atrial flutter, PSVT, or ventricular tachycardia.

[0017] In some configurations, ablating the first cardiac target tissue includes delivering an ablative direct current.

[0018] In some configurations, ablating the first cardiac target tissue comprises delivering RF energy, microwave energy, ultrasound energy, cryoablation, thermal energy, and / or laser energy. In some configurations, ablating the first cardiac target tissue comprises delivering cryoablation.

[0019] In some configurations, a method of performing a cardiac electrophysiology study in a patient is disclosed, comprising sensing electrical activity of a first cardiac target tissue; delivering a first non-ablative current to the first cardiac target tissue sufficient to produce a reversible conduction block in the first cardiac target tissue; and observing abnormal electrical activity in the patient's heart after delivering the first non-ablative current. The non-ablative current may include HFAC and / or direct current. The method may also include ablating the first cardiac target tissue if there is a lack of abnormal electrical activity after delivering the first non-ablative current to the first cardiac target tissue.

[0020] In some configurations, an electrophysiological cardiac ablation system is disclosed herein, comprising a first generator configured to generate a non-ablative blocking current; a second generator configured to generate an ablative energy modality; and a catheter. The catheter has a proximal end and a distal end, the proximal end being configured to be connected to the first generator and a second ablative reservoir, which may be a second generator. The catheter may also include a conductor extending from a proximal region of the catheter to a distal region of the catheter. The conductor may be disposed inside the integrated catheter. The system may also include at least one blocking electrode disposed at the distal end of the catheter and configured to be conductively connected to the first generator; and at least one ablation end effector disposed at the distal end of the catheter and configured to be conductively connected to the second ablative reservoir, which may be, for example, an RF generator, an ultrasonic generator, a microwave generator, a cryoprecipitate reservoir, etc. The system may also be configured to produce a reversible blockage in cardiac tissue by delivering a blocking current from the first generator to the cardiac tissue via at least one blocking electrode. The system can also be configured to ablate cardiac tissue by delivering an ablative energy modality from the second generator to the at least one ablation electrode.

[0021] In some configurations, at least one blocking electrode includes a high charge density material.

[0022] In some configurations, at least one blocking electrode is made of silver and / or silver chloride, and / or titanium nitride.

[0023] In some configurations, the first generator is configured to generate non-ablative DC or HFAC.

[0024] In some configurations, the conductor includes a wire.

[0025] In some configurations, at least one occluding electrode is configured to sense cardiac tissue activity.

[0026] In some configurations, at least one ablation electrode encompasses a circumference of a portion of the distal end of the catheter.

[0027] In some configurations, at least one ablation electrode is an RF ablation electrode.

[0028] In some configurations, the catheter is flexible enough to allow contact between the at least one occlusion electrode and cardiac tissue.

[0029] In some configurations, the at least one occluding electrode is placed on an expandable member such as a balloon positioned proximate a distal end of the integrated catheter, and the balloon is configured to be inflated so that the at least one occluding electrode can directly contact the heart tissue.

[0030] In some configurations, an electrophysiological cardiac ablation system is disclosed herein, which may include a generator configured to generate a non-ablative blocking current; and a catheter. The catheter may include a proximal end and a distal end, the proximal end being configured to be coupled to the generator. The catheter may include an inner cavity extending from a proximal region of the integrated catheter to a distal region of the integrated catheter, defining openings within the proximal region and the distal region. The inner cavity is configured to facilitate a conductive fluid flowing from the proximal region of the catheter to the distal region of the catheter. The catheter may also include at least one ablation electrode, which is disposed proximal to the distal region of the integrated catheter and is configured to be conductively connected to the generator. The system may be configured to reversibly block cardiac tissue by delivering a non-ablative blocking current from the generator to the cardiac tissue via a conductive fluid. The system may also be configured to ablate cardiac tissue by delivering an electric current from the generator to at least one ablation electrode. The conductive fluid may be a volume of conductive fluid including saline, for example, and is configured to carry a DC current to reversibly block cardiac tissue. The ablation electrode may be, for example, an RF electrode or another end effector such as a microwave antenna, a laser, a cryoport, an ultrasound transducer, or the like.

[0031] In some configurations, an integrated catheter is disclosed herein, comprising a proximal end configured to be coupled to a generator; a distal end; at least one occluding electrode disposed proximate to the distal end of the integrated catheter and configured to be conductively connected to the generator; and at least one ablation electrode disposed proximate to the distal end of the integrated catheter and configured to be conductively connected to the generator. The integrated catheter is configured to occlude cardiac tissue by delivering an occluding current from the generator to the cardiac tissue via the at least one occluding electrode; and is configured to ablate cardiac tissue by delivering an electric current from the generator to the at least one ablation electrode. In some embodiments, at least one electrode is configured to sense cardiac tissue activity. The sensing electrode may be integrated with the ablation end effector and / or the non-ablative current electrode, or in some embodiments may be an independent electrode.

[0032] BRIEF DESCRIPTION OF THE DRAWINGS

[0033] In the detailed description below, reference is made to the drawings that are a part thereof. In the drawings, similar symbols generally identify similar components unless the context otherwise indicates. Therefore, in some embodiments, part numbers may be used for similar components in multiple figures, or part numbers may vary from figure to figure. The illustrative embodiments described in the detailed description, drawings, and claims are not intended to be restrictive. Other embodiments may be utilized and other changes may be made without departing from the spirit or scope of the subject matter presented herein. It is readily understood that the various aspects of the present disclosure as generally described herein and shown in the drawings may be arranged, replaced, combined, and designed in a variety of different configurations, all of which are expressly contemplated and constitute a part of the present disclosure.

[0034] Figure 1A An exemplary graph showing obstructive DC amplitude as a function of time is shown.

[0035] Figure 1B Exemplary graphs showing EP assessments of the efficacy of testing DC blockade on cardiac tissue as a function of time are shown.

[0036] Figure 1C An exemplary graph is shown illustrating ablation applied to cardiac tissue as a function of time.

[0037] Figure 2 An exemplary EP cardiac ablation system using a conductive fluid is schematically illustrated.

[0038] Figure 3 An exemplary EP cardiac ablation system using a non-fluid conductor is schematically illustrated.

[0039] Figure 4 An exemplary EP cardiac ablation system using a non-fluid conductor and a particle container is schematically illustrated.

[0040] Figure 5A An exemplary EP cardiac ablation system using an integrated catheter and conductive fluid is schematically illustrated.

[0041] Figure 5B An exemplary EP cardiac ablation system using an integrated catheter and conductive fluid is schematically illustrated.

[0042] Fig. 6A An exemplary EP cardiac ablation system using an integrated catheter and non-fluid conductor is schematically illustrated.

[0043] Figure 6B An exemplary EP cardiac ablation system using an integrated catheter, non-fluid conductor, and particle container is schematically illustrated.

[0044] Figure 7An exemplary graph is shown illustrating the desired level of cardiac tissue ablation as a function of DC current amplitude.

[0045] Fig. 8A An exemplary blocking mode is schematically illustrated.

[0046] Figure 8B Exemplary ablation patterns are schematically illustrated.

[0047] Fig. 9 An exemplary mapping catheter is schematically shown.

[0048] Fig.10 An exemplary EP cardiac ablation system using a deformable grid is schematically illustrated.

[0049] Fig.11 An exemplary EP cardiac ablation system using a balloon is schematically illustrated. DETAILED DESCRIPTION OF THE INVENTION

[0051] Although certain embodiments and examples are described below, the present disclosure extends beyond the specifically disclosed embodiments and / or uses and obvious modifications and equivalents thereof. Therefore, it is intended that the scope of the present disclosure should not be limited by any specific embodiments described below.

[0052] Applying direct current (DC) can advantageously produce a reversible, non-ablative blockade of cardiac tissue. Without being limited by theory, DC can advantageously inactivate sodium channels, thereby causing a robust blockade of tissue at low amplitudes. In addition, DC can also cause a continuous inward flow of ions (such as calcium, sodium, or potassium ions), thereby causing a robust blockade of tissue at low amplitudes. Alternatively or additionally, a high-frequency alternating current (AC) can be applied to produce a reversible blockade of cardiac tissue. In some embodiments, high-frequency AC can be applied in conjunction with DC. This may be in contrast to the conventional ablation (or defibrillation) of tissues using DC. Some embodiments relate to systems and electrodes for safely delivering blocking direct current (DC) to non-neural tissues, such as cardiac tissues, by delivering circulating cathode currents and anode currents via high-charge chemicals.

[0053] Without being limited by theory, the propagation of action potentials in non-neural tissues, such as cardiac tissue, causes a millisecond refractory period of sodium channels, typically 1-20 ms for a combination of absolute and relative refractory periods, and therefore, very low frequency AC current waveforms having a half-cycle significantly greater than this refractory period (e.g., greater than about 50 ms) can also be used to produce tissue blockade and be considered as direct current stimulation by the cardiac tissue. Thus, direct current as defined herein includes low frequency AC current waveforms that are considered and functionally direct current from the perspective of the tissue whose action potential is modulated. The frequency can be, for example, less than about 1 Hz, 0.5 Hz, 0.1 Hz, 0.05 Hz, 0.01 Hz, 0.005 Hz, 0.0001 Hz, or a range including any two of the foregoing values, as long as the direction of the current is constant over at least the entire refractory period of the target cardiac tissue.

[0054] Direct current has been used to block neural tissue, including brain tissue, central nervous system and peripheral nerves, including but not limited to somatic and autonomic nerves (e.g., sympathetic and parasympathetic nervous systems). In some embodiments as described herein, non-neural, electrically excitable / conductive tissues can be advantageously treated to produce a reversible blockade, including myocardial tissue.

[0055] In some embodiments, one or more portions of the conduction system of the heart, including the SA node, AV node, bundle of His, left bundle, right bundle, bundle of Bachmann, anatomical variability accessory pathways, such as the bundle of Kent or Purkinje fibers, can be reversibly treated with non-ablative DC and / or HFAC. In some embodiments, the treatment does not include one or all of the above-mentioned portions of the cardiac conduction system. Alternatively or additionally, cardiac tissue, e.g., myocardial tissue that is not part of the cardiac electrical conduction system described above, can be treated with systems and methods as disclosed herein.

[0056] Direct current systems and methods can be implemented to prevent ablation after DC administration (thereby preserving tissue). This can facilitate testing whether a specific portion / region of cardiac tissue is suitable for therapeutic ablation relative to iatrogenic ablation (e.g., reversibly testing whether ablation of a given tissue is indeed therapeutic).

[0057] Subsequent ablation of the tissue may be performed, including but not limited to electromagnetic energy delivery (e.g., RF, microwave, ultrasound, laser, and / or magnetic energy), thermal ablation, cryoablation, chemical ablation, mechanical ablation (e.g., Maze procedure), combinations of the above, etc. In some embodiments, ablative DC may also be used to ablate or permanently alter tissue (e.g., much higher intensity DC than used to generate heat and / or destructive / ablative electrochemical agents, or reversible blocking by replacement electrodes).

[0058] Compared with the DC current that causes ablation, the DC current used to produce temporary blockage of cardiac tissue can have a significantly lower amplitude. For example, 0.1-20mA, 0.1-5mA, 0.1-10mA, 1.0-10mA, 5-20mA, 10-20mA, 5-50mA or 20-100mA can be used to temporarily block cardiac tissue, or less than about 100mA, 50mA, 20mA, 10mA, 5mA, 1mA, 0.5mA, 0.1mA or even smaller, or a range including any two of the above values. The system described herein can facilitate the safe, non-ablative delivery of DC within these ranges. In some cases, the amplitude of the DC may be tilted up or down, including a nonlinear ramp function. In some embodiments, the duration of DC delivery can only be applied during the period during which the practitioner wishes to create a blockade (e.g., simulated ablation). In some embodiments, any delivery or transition period can be, for example, at least about, about, or no more than about 1 second, 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, 30 seconds, 35 seconds, 40 seconds, 45 seconds, 50 seconds, 55 seconds, 60 seconds or more seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes or more minutes, or a range including any two of the foregoing values.

[0059] In some embodiments, high frequency as used herein with reference to alternating current (e.g., HFAC) can refer to about 1 kHz or higher, such as about 1.5 kHz to about 100 kHz, about 3 kHz to about 50 kHz, about 5 kHz to about 20 kHz, about 1 kHz, 2 kHz, 3 kHz, 5 kHz, 10 kHz, 15 kHz, 20 kHz, 25 kHz, 30 kHz, 40 kHz, 50 kHz, 75 kHz, 100 kHz or more, or a frequency of a range including any two of the above values. In some embodiments, the amplitude of the signal can range from about 0.1 mA to about 20 mA, about 0.5 mA to about 10 mA, about 0.5 mA to about 4 mA, about 0.5 mA to about 2.5 mA, or other ranges including any two of the above values, or other amplitudes as disclosed elsewhere herein. In some cases, the amplitude of the applied signal can be ramped up and / or down, including nonlinear ramp functions. The frequency or amplitude of the alternating current can also be adjusted.

[0060] With reference to the figures disclosed herein, the blocking device may be independent / separate from the ablation device. In some embodiments, the blocking device and the ablation device may be integrated. Exemplary systems include, but are not limited to, those shown in the figures disclosed herein.

[0061] refer to Figure 1A-Figure 1CBlocking DC may be used alternately with ablative modalities, including but not limited to RF (or other ablation techniques), to guide the depth of ablation of tissue or therapeutic ablation areas that may be more tissue-sparing or faster than ablation without the use of blocking DC.

[0062] Figure 1A An exemplary graph 100 is shown that illustrates blocking DC amplitude as a function of time as applied to cardiac tissue. Vertical axis 102 is blocking DC amplitude measurement. Horizontal axis 104 is time. Blocking DC amplitude 106 is configured when time equals zero. Blocking DC amplitude 108 is placed at a subsequent time. Blocking DC amplitude 108 can be a higher DC amplitude than blocking DC amplitude 106. In some embodiments, blocking DC amplitude 108 can have the same or smaller amplitude than blocking DC amplitude 106.

[0063] Figure 1B An exemplary graph 110 is shown, which shows an EP assessment of the efficacy of testing DC blocking applied to cardiac tissue as a function of time. The vertical axis 112 is the EP assessment metric. The horizontal axis 114 is time. After time zero, a first test 116 of blocking efficacy is performed and blocking DC is applied to cardiac tissue. A second test 118 of efficacy is performed at a time after the time associated with the first test 116 of efficacy. A third test (and subsequent) 119 of efficacy is performed at a time after the time associated with the second test 118 of efficacy.

[0064] Figure 1C An exemplary graph 120 is shown which shows ablation as a function of time. The vertical axis 122 is the ablation metric. The horizontal axis 124 is time. Figure 1B A first ablation 126 is applied some time after the first test 116 of efficacy in the present invention. A second ablation 128 is applied some time after the first ablation 126. The ablation metric 128 can be a higher or lower ablation metric than the ablation metric 126. In some embodiments, the ablation metric 128 can have the same or smaller amplitude than the ablation metric 126.

[0065] In some embodiments, additional ablations may also be performed, such as a 3rd, 4th, 5th, and subsequent ablations. In some embodiments, multiple assessments / tests may be performed before or after an ablation event, such as about or at least about 2, 3, 4, 5, or more assessments / tests (e.g., observing the presence of target features, such as pathological arrhythmias and / or abnormal electrical activity, and the application of non-ablative blocking currents). In some embodiments, at least 1, 2, or more ablation events may be performed after the assessment, such as about or at least 2, 3, 4, 5, or more ablation events. In some embodiments, only assessments / tests are performed during the procedure without any ablation events, including when no obvious cause of the patient's symptoms has been identified.

[0066] Figure 2 An exemplary system 200 having a fluid conduit coupled to an external generator is shown. The system 200 can have a generator 202. In some embodiments, the generator 202 can supply a DC current. In some embodiments, the generator 202 can supply an AC current, such as HFAC. The generator 202 can have a cathode (and / or anode) conductor 204. The generator can include a loop anode and / or cathode (e.g., a patch electrode placed on the patient's skin).

[0067] The generator 202 can be configured to be coupled to a catheter 206. The catheter 206 can have a proximal end and a distal end. In some embodiments, the generator 202 can be detachably coupled to the proximal end of the catheter 206.

[0068] The catheter 206 can be an elongated tube. The catheter 206 can have a lumen extending from the proximal end to the distal end of the catheter 206 (or from other distances along the catheter 206 to or near the distal end of the catheter 206). The catheter 206 can have outer diameters of different sizes. The lumen can define the inner diameter of the catheter 206 of different sizes. The catheter 206 can have different lengths extending from the proximal end to the distal end of the catheter 206.

[0069] The lumen of the catheter 206 can be configured to hold a conductive fluid 208. In some embodiments, the conductive fluid 208 can be saline and / or another suitable fluid. In some embodiments, the generator 202 can generate an electric current flowing through the conductive fluid 208.

[0070] The lumen of the catheter 206 can be configured to carry the conductive fluid 208 from the proximal region to one or more openings in the distal region, including one or more openings along the sidewall of the elongated, for example, tubular structure. In some embodiments, the opening is arcuate, such as a circular, elliptical or other hole, but may also include a partially circumferential, longitudinal or spiral groove, and / or other geometric shapes. The distal end of the catheter 206 can be positioned through an anatomical cavity in the patient so that the distal end of the catheter 206 is adjacent to the cardiac tissue. Once positioned, the generator 202 can generate an electric current carried by the conductive fluid 208. The conductive fluid 208 can be carried from the proximal region of the catheter 206 to the distal region, and ultimately makes direct contact or at least electrical contact with the cardiac tissue of the patient.

[0071] The catheter 206 may be made of different materials that facilitate carrying the electrically charged conductive fluid 208 and / or insertion into a patient.

[0072] Figure 3 An exemplary system 300 for using an electrode at the distal end of a catheter is shown. The exemplary system 300 can have a generator 302. The generator 302 can have features of the generator 202.

[0073] Generator 302 can be configured to couple with catheter 306. Catheter 306 can have features of catheter 206. Catheter 306 can have a non-fluid conductor 304 disposed within catheter 306. In some embodiments, non-fluid conductor 304 is a wire. In some embodiments, generator 302 can couple with non-fluid conductor 304.

[0074] The catheter 306 can have a distal electrode 308 disposed at or near the catheter 306. In some embodiments, the electrode 308 is a non-ablative DC electrode. In some embodiments, the electrode 308 can apply DC and / or AC (e.g., HFAC) current. In some embodiments, the electrode 306 is configured to apply a non-ablative current to the patient's cardiac tissue. In some embodiments, the electrode 308 surrounds all or part of the outer perimeter of the catheter 306. In some embodiments, the electrode 308 includes a plurality of electrodes.

[0075] Electrode 308 can be composed of a variety of substances. In some embodiments, electrode 308 can be made of silver (Ag) and / or silver chloride (AgCl). In some embodiments, electrode 308 can be made of titanium nitride (TiN). In some embodiments, electrode 308 can be composed of carbon (C). In some embodiments, electrode 308 has an ion-selective coating or membrane. In some embodiments, electrode 308 does not have an ion-selective coating or membrane.

[0076] In some embodiments, the electrode may include a contact comprising a high charge-carrying material. The electrode contact may have a diameter of about 1 mm in some cases. 2 To about 10mm 2 , or about 1mm 2 , 2mm 2 , 3mm 2 , 4mm 2 , 5mm 2 , 6mm 2 , 7mm 2 , 8mm 2 , 9mm 2 , 10mm 2 , 20mm 2 , 50mm 2 , 100mm 2 The electrode contact itself can be made of high charge-carrying materials, such as those described in U.S. Patent No. 10,071,241 of Bhadra et al., which are hereby incorporated by reference in their entirety. Alternatively, the electrode contact can include a substrate coated at least partially or completely with a high charge-carrying material. In some embodiments, the high charge-carrying material can have at least about 25, 50, 100, 200, 300, 400, 500, 1,000, 2,500, 5,000, 10,000, 50,000, 1000,000, 500,000 or higher μC, or a Q value including the range of any two of the above values. The Q value of the electrode contact can refer to the total charge that can be transported by the electrode contact before the electrode contact begins to undergo an irreversible chemical reaction, such as the precipitation of oxygen or hydrogen or the dissolution of the electrode material. Non-limiting examples of high-charge-carrying materials are platinum black, iridium oxide, titanium nitride, tantalum, silver chloride, poly(ethylenedioxythiophene) and suitable combinations thereof. In some embodiments, the electrode may be a fractal-coated electrode. In order to produce a larger surface area for electrochemical reactions, conventional electrodes may be made from structures with a high surface area-to-volume ratio, such as a rough surface, a woven surface, a patterned surface, a reticular foam structure, a porous sintered microbead structure, a nanoscale or micrometer-scale patterned structure, to expose additional material surface area. In some embodiments, the electrode may be a SINE (separated interface neural electrode) or an EICCC (electron to ion current conversion cell) electrode, wherein the electrode is immersed in an electrolyte solution, which is in contact with an ionic conductive material-electrolyte solution interface having an ionic conductive material in electrical contact with cardiac tissue or an area close to cardiac tissue, such as, for example, U.S. Pat. No. 9,008,800 of Ackermann et al. and U.S. Publication No. 2018 / 0280691 of Ackermann et al., which are hereby incorporated herein by reference in their entirety.

[0077] In some embodiments, the system may include silver and / or silver chloride electrodes, such as those described in U.S. Publication No. 2018 / 0280691 of Ackermann et al., which is hereby incorporated by reference in its entirety herein. A system for patient cardiac tissue obstruction may utilize regenerative electrodes in some cases. The system may include a direct current generator and / or at least one electrode including silver chloride. The system may also include a controller configured to send a signal to the direct current generator to form an electrode of solid silver and chloride ions by sufficient to block conduction in the cardiac tissue, and / or reduce the amount of silver chloride in the electrode, thereby conveying a first direct current with a first polarity. The controller may also be configured to send a signal to the direct current generator to convey a second direct current with a second polarity by an electrode sufficient to increase the amount of silver chloride, thereby regenerating the electrode. The system may also include a cardiac tissue interface separated from the electrode by a selective barrier. The selective barrier may also be configured to allow specific ions, such as chloride ions, to pass through the barrier toward the cardiac tissue interface to block the cardiac tissue. The system may also include a sensor configured to determine whether a reaction, such as a predominantly silver / silver chloride reaction, is occurring. The controller may also be configured to receive data from the sensor and interrupt or adjust at least one of the first DC signal or the second DC signal when an undesirable activity, such as water electrolysis, occurs. The selective barrier may also be configured to prevent silver ions from passing through the barrier toward the cardiac tissue interface. The electrode may be encapsulated in an insulating housing. The selective barrier may include an ion exchange membrane and / or a hydrogel. In some cases, the system may not have any mechanical moving parts. The controller may be configured to deliver the first DC current so that the amount of silver chloride reduced is greater than the surface area of ​​the electrode before delivering the first DC current. The controller can also be configured to deliver the first direct current so that the amount of silver chloride reduced is greater than, such as to uniformly cover the surface area, such as about 1.25x, 1.5x, 2x, 3x, 4x, 5x, 10x, 15x, 20x, 50x, 100x, 1,000x, 5,000x, 10,000x or more times the entire functional surface area of ​​the electrode prior to delivering the first direct current, or a range including any two of the foregoing values.

[0078] The distal end of catheter 306 and electrode 308 can be placed adjacent to cardiac tissue. Generator 202 can generate an electrical current that is carried to electrode 308 via non-fluid conductor 304. The electrical current can pass through electrode 308 to target cardiac tissue.

[0079] Figure 4 An exemplary system 400 is shown that can employ Ag and / or AgCl electrodes, which are used without the need for ion selective coatings. The system 400 can have a generator 302. The system 400 can include a conduit 306.

[0080] In some embodiments, the electrode 308 may be made of Ag and / or AgCl and no ion selective coating is required. This configuration may be suitable for temporary use, as Ag dissolution will be minimal during the ablation procedure.

[0081] The particle container 402 can be placed around the electrode 308. In some embodiments, the particle container 402 can be a sponge, a basket, a net, and / or some other similar device to prevent the particles from escaping. In some embodiments, no particle container 402 is located around the electrode 308. The particle container 402 can be made of a variety of materials that are conducive to surrounding the electrode 308 and capturing particles that may be separated from the electrode 308.

[0082] Figure 5A An exemplary system 500 for an integrated occlusion and ablation catheter is shown. In some embodiments, occlusion is performed using DC and / or AC current. In some embodiments, ablation is performed using RF ablation or another suitable ablation technique, such as thermal ablation or cryoablation, or other techniques such as those disclosed elsewhere herein. This configuration can be incorporated into any delivery technique disclosed herein.

[0083] System 500 may include generator 502. Generator 502 may have features of other generators disclosed herein. Generator 502 may be coupled to a proximal end of catheter 506. Catheter 506 may have features of other catheters disclosed herein. Conductive fluid 504 may flow through catheter 506—from the proximal end to an opening in the distal end. The current generated by generator 502 may be carried from the proximal end to the distal end of catheter 506 by conductive fluid 504. The charged conductive fluid 504 may be applied to cardiac tissue.

[0084] Electrode 508 can be located on the distal end of catheter 506. Electrode 508 can be an RF ablation electrode. In some embodiments, electrode 508 can be, for example, a suitable ablation electrode, such as those that will facilitate thermal ablation or cryoablation. In some embodiments, electrode 508 is conductively connected to generator 502 so that the generated current can flow to electrode 508. Electrode 508 can be made of various materials. Electrode 508 can have the features of other electrodes disclosed herein.

[0085] Figure 5B A partial view 512 of the system 500 is shown. The conductive fluid 504 can flow out of the distal or side openings 510 to exit the lumen of the catheter 506.

[0086] References FIG. 5A to FIG. 5BThe described configuration may be advantageous because occlusion and ablation delivery are integrated within the same catheter. The configuration may facilitate testing of occlusion current and ablation utilizing the same cardiac tissue (e.g., which would otherwise be difficult to test using two or more catheters). The configuration may increase the speed of EP cardiac ablation procedures. In some embodiments, the conductive fluid 504 may function both as a non-ablative block for current conduction and as a temperature regulator during peri-ablation (e.g., by cooling the system after a thermal event caused by RF ablation).

[0087] Fig. 6A An exemplary system 600 for an integrated occlusion and ablation catheter is shown. The exemplary system 600 can include a generator 602. The generator 602 can have features of other generators disclosed herein.

[0088] The generator 602 can be coupled to a catheter 606. The catheter 606 can have the features of other catheters disclosed herein. The catheter 606 can have a non-fluid conductor 604 configured to carry current from the generator 602 to the distal end of the catheter 606. The distal end of the catheter 606 can have an opening exposing an electrode core 610. In some embodiments, the electrode core 610 is a non-ablative DC electrode. In some embodiments, the electrode core 610 is made of Ag and / or AgCl. In some embodiments, the electrode core can be made of another conductive material. The current can be carried from the generator 602 through the non-fluid conductor 604 and applied to the patient's cardiac tissue via the electrode core 610.

[0089] The distal end of catheter 606 has an electrode 608. Electrode 608 can have features of other electrodes disclosed herein. In some embodiments, electrode 608 is an RF ablation electrode. Electrode 608 can be conductively connected to generator 602 so that the generated current can flow from generator 602 to generator 602.

[0090] Figure 6B An exemplary system 614 is shown that includes an integrated occlusion and ablation catheter with a particle container. The particle container 612 can be placed around the electrode 608. In some embodiments, the entire electrode 608 is covered by the particle container 612. The particle container 612 can be a grid, a sponge, a basket, and / or some other device that prevents particles from escaping.

[0091] References Fig. 6A and Figure 6B The described configuration may be advantageous because occlusion and ablation delivery are integrated into the same catheter.

[0092] Figure 7An exemplary graph 700 is shown showing the desired ablation level as a function of the DC current amplitude that may be associated.RF, cryo or other ablations may be delivered at dose levels predicted by the amplitude of the DC current required to achieve the desired therapeutic occlusion, such as to achieve the desired ablation depth.

[0093] The vertical axis 702 is the desired ablation level. The horizontal axis 704 is the DC current amplitude. For example, if a DC amplitude of "x" 708 is required to achieve a desired level of therapeutic effect, then an ablation level (e.g., power and / or duration) of about "y" 706 or higher or lower is delivered to ablate a similar volume of cardiac tissue.

[0094] Fig. 8A An exemplary blocking pattern 800 is shown. Application of the blocking pattern 800 can include applying the integrated catheter 804 to the cardiac tissue 806. The current can be applied to the cardiac tissue 806 via the blocking conductor 802, which can be an electrode, an electrode core, a non-fluid conductor, and / or a conductive fluid of the integrated catheter 804. In some embodiments, the blocking conductor 802 applies a blocking DC current to the cardiac tissue 806. A cathodic current that exceeds the anodic current can preferably be applied to directly block the cardiac tissue 506 under the blocking conductor 802. Region 808 can illustrate the blocked volume of the cardiac tissue 806 resulting from the current flowing from the blocking conductor 802 to the cardiac tissue 806. The delivered current can be Figure 7 The "x" 708 shown in FIG.

[0095] An anodic current may also be applied (e.g., a lower amplitude anodic current may increase excitability of cardiac tissue proximal to the electrode to confirm its role in cardiac arrhythmias). In some embodiments, the integrated catheter 804 may be articulated to create a bend with one or more degrees of freedom in the integrated catheter 804. In some embodiments, the integrated catheter 804 may be used to measure biopotentials from cardiac tissue 806. In some embodiments, the blocking conductor 802 may be used to measure biopotentials when a blocking current is not delivered and / or not simultaneously with the delivery of a current.

[0096] Figure 8B An exemplary ablation pattern 810 is shown. Application of ablation pattern 810 may include applying integrated catheter 804 to tissue 806. Ablation electrodes 812, which may be positioned around the exterior of blocking conductor 802, may ablate cardiac tissue 806. Region 814 may illustrate an ablated volume of cardiac tissue 806. In some embodiments, the volume of region 814 may be similar to the volume of region 808. The level of ablation may be Figure 7 "y" 706 is shown in FIG.

[0097] Fig. 9An exemplary mapping catheter 900 is shown. The mapping catheter can have an elongated portion 902 without contacts. The mapping catheter 900 can have a series of contacts 904 located on and / or near the distal end of the mapping catheter 900. The contacts 904 can be electrodes. In some embodiments, the contacts 904 can have the features of the electrodes disclosed herein.

[0098] In some embodiments, contacts 904 surround a circumferential portion of conduit 900. In some embodiments, contacts 904 are equally spaced from one another. In some embodiments, contacts 904 have different spacings from one another. In some embodiments, contacts 904 are the same size. In some embodiments, contacts 904 have different sizes.

[0099] In some embodiments, contact 904 is made of Ag and / or AgCl. In some embodiments, contact 904 is coated with, for example, an anion exchange membrane. In some embodiments, contact 904 is surrounded by a particle container, which may include a basket, a grid, and / or other coverings. In some embodiments, contact 904 is coated with, for example, an anion exchange membrane. In some embodiments, contact 904 is made of a high charge density material such as TiN or porous TiN.

[0100] Current may be delivered through one or more contacts 904 of the mapping catheter 900. In some embodiments, DC current and / or AC current is delivered. This may help assess whether one or more ablations may be therapeutic. In some embodiments, the contacts 904 may be selected singly or in multiples, for example, to record, block, and / or stimulate in multiples.

[0101] Contact 904 may be used to control the current flow and / or select which portion of the heart tissue to occlude.

[0102] Contact 904 and the blocking electrodes disclosed herein may have one or more other features, such as ultrasound.

[0103] Any catheter disclosed herein can have the form of a mapping catheter, such as mapping catheter 900. Catheter 900 and any catheter disclosed herein can have a flexible element capable of intimate contact with cardiac tissue. Catheter 900 and any catheter disclosed herein can have an addressable DC blocking contact that can deliver DC to cardiac tissue to provide safe and reversible blocking of action potentials in the target tissue.

[0104] Fig.10 An exemplary system 1000 is shown. The exemplary system 1000 can have a generator 1002. The generator 1002 can have features of the generators disclosed herein. The generator 1002 can be coupled to a catheter 1006. The catheter 1006 can have features of other catheters disclosed herein.

[0105] The catheter 1006 can have a non-fluid conductor 1004 that conducts current from the generator 1002 to contacts, electrodes, and / or wires placed on the mesh member 1008. The mesh member 1008 can be placed on the distal end of the catheter 1006. In some embodiments, the mesh member 1008 is deformable after contacting the heart tissue. In some embodiments, the mesh member 1008 can be a meshed deformable sphere with surface contacts (electrodes) positioned along the outer perimeter. The mesh member 1008 can be a meshed deformable sphere with wires extending along the outer perimeter. In some embodiments, the surface contacts and / or wires can be positioned so that they are longitudinally or perpendicular to the longitudinal direction relative to the main axis of the mesh member 1008. In some embodiments, the non-fluid conductor 1004 can address the surface contacts and / or wires individually or separately.

[0106] Fig.11 An exemplary system 1100 is shown. The exemplary system 1100 can have a generator 1102. The generator 1102 can have features of the generators disclosed herein. The generator 1102 can be coupled to a catheter 1106. The catheter 1106 can have features of other catheters disclosed herein.

[0107] The catheter 1006 can have a non-fluid conductor 1104 that conducts current from the generator 1102 to a conductor 1110 (e.g., contact, electrode, and / or wire) disposed outside of an expandable member, such as a balloon 1008, an expandable cage, or the like. The conductor 1110 can be a DC blocking electrode contact. In use, the balloon 1008 can be inflated to bring the conductor 1110 into close contact with the heart tissue. In some embodiments, this can facilitate improved current delivery to block the heart tissue, which can include DC current delivery.

[0108] In some embodiments, electrodes and / or contacts may include DC blocking electrode contacts that are capable of sensing activity in cardiac tissue. This may apply to any electrode, contact, and / or system disclosed herein. In some embodiments, other sensing contacts may be placed in close proximity to electrodes and / or contacts, which may include DC blocking electrode contacts. This may apply to any electrode, contact, and / or system disclosed herein.

[0109] In some embodiments, the return path of the circuit can be through distal electrodes and / or catheter-based electrodes. The distal electrodes can include patch electrodes placed on the skin, distal catheters. The distal electrodes can be used to allow for more substantially symmetrical access to the volume of ablated tissue as the ablative modality is delivered.

[0110] Embodiments of methods for conducting electrophysiological studies and ablation procedures are now described. Vascular access may be obtained percutaneously (e.g., femoral vein, internal jugular vein, radial artery, or brachial artery, etc.) or by incision. A guidewire may be inserted and a catheter may be passed over the guidewire to a desired position close to the heart. Imaging, such as fluoroscopy or other guidance may be utilized. In some cases, sensing electrodes may be moved along a conductive path and along and within the endocardium to measure electrical activity. The heart or its chambers may then be paced to observe abnormalities. Arrhythmias may then be stimulated in an attempt to induce arrhythmias via stimulating currents and / or arrhythmic pharmacological agents (including but not limited to epinephrine, dopamine, phenylephrine, isoproterenol, aminophylline, calcium, atropine, or other agents), and sensing electrode movement may be performed to locate the source of abnormal electrical activity. Non-ablative DC or HFAC may be delivered to a first target region of cardiac tissue, which is believed to be the source of abnormal electrical activity, via electrodes on a catheter. If the arrhythmia stops, the first target area can be effectively ablated using RF or other ablation techniques such as those disclosed herein. If the arrhythmia does not stop, the first target area is retained and the second target area is treated with non-ablative DC or HFAC. If the arrhythmia stops, the second target area can be effectively ablated using RF or other ablation techniques such as those disclosed herein. If the arrhythmia does not stop, the second target area is retained and a search for a third target area can be started and the process can be repeated.

[0111] In some embodiments, non-ablative occlusion can be used in conjunction with a pulmonary vein isolation procedure. After the catheter is advanced across the septum to the ostium of the pulmonary vein, the non-ablative occlusion can be directed circumferentially around the ostium of the pulmonary vein. A temporary circumferential ablation zone is thereby created that effectively blocks electrical propagation between the pulmonary vein and the left atrium. If the arrhythmia is no longer inducible, a permanent circumferential ablation lesion can be created via ablative approaches, including those described elsewhere herein.

[0112] In some embodiments, some non-limiting conditions that can be treated with the systems and methods disclosed herein can include, but are not limited to, atrial fibrillation (such as chronic or paroxysmal atrial fibrillation), long QT syndrome, Wolff-Parkinson-White syndrome, torsades de pointes, premature atrial beats, wandering atrial pacemaker, multifocal atrial tachycardia, atrial flutter, supraventricular tachycardia (including PSVT), atrioventricular nodal reentrant tachycardia, junctional rhythm, junctional tachycardia, premature junctional complex, premature ventricular contraction, accelerated ventricular autonomous rhythm, monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, right ventricular outflow tract tachycardia, and ventricular fibrillation.

[0113] Although the present disclosure has been described in the context of certain embodiments and examples, it will be understood by those skilled in the art that the present disclosure extends from the specific disclosed embodiments to other optional embodiments and / or uses and obvious modifications and equivalents thereof. In addition, although several variations of the embodiments of the present disclosure have been shown and described in detail, it will be readily apparent to those skilled in the art that other modifications within the scope of the present disclosure will be readily apparent. It can also be expected that various combinations or sub-combinations can be made to the specific features and aspects of the embodiments, and still fall within the scope of the present disclosure. For example, the features described above in conjunction with an embodiment can be used together with the different embodiments described herein, and the combination still falls within the scope of the present disclosure. It should be understood that the various features and aspects of the disclosed embodiments can be combined or substituted with each other to form different modes of the embodiments of the present disclosure. Therefore, it is intended that the scope of the disclosure herein should not be limited by the above-mentioned specific embodiments. Therefore, unless otherwise stated, or unless clearly incompatible, each embodiment of the present invention, in addition to its basic features described herein, may also include one or more features as described herein from each other embodiment of the present invention disclosed herein.

[0114] Features, materials, characteristics or groups described in conjunction with a particular aspect, embodiment or example are to be understood to be applicable to any other aspect, embodiment or example described in this section or elsewhere in this specification unless incompatible therewith. All features disclosed in this specification (including any accompanying claims, abstract and drawings), and / or all steps of any method or process so disclosed, may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. Protection is not limited to the details of any foregoing embodiments. Protection extends to any novel feature or any novel combination of features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel step or any novel combination of steps of any method or process so disclosed.

[0115] In addition, certain features described in the context of separate embodiments in this disclosure may also be implemented in combination in a single embodiment. Conversely, various features described in the context of a single embodiment may also be implemented separately in multiple embodiments or in any suitable sub-combination. In addition, although features may be described above as functioning in certain combinations, in some cases, one or more features from the claimed combination may be severed from the combination, and the combination may be referred to as a sub-combination or a variation of a sub-combination.

[0116] In addition, although operations can be depicted in the drawings or described in the specification in a particular order, it is not necessary to perform such operations in the particular order shown or in a continuous order, or it is not necessary to perform all operations to obtain the desired result. Other operations not shown or described can be incorporated into the exemplary method and process. For example, one or more additional operations can be performed before, after, simultaneously or between any of the operations. In addition, in other embodiments, operations can be rearranged or reordered. It will be understood by those skilled in the art that in some embodiments, the actual steps taken in the process shown and / or disclosed may be different from the steps shown in the figure. Depending on the embodiment, some of the above steps can be removed and other steps can be added. In addition, the features and attributes of the specific embodiments disclosed above can be combined in different ways to form other embodiments, all of which fall within the scope of the present disclosure. Similarly, the separation of various system components in the above-mentioned embodiments should not be understood as requiring such separation in all embodiments, and it should be understood that the described components and systems can generally be integrated together into a single product or packaged as multiple products.

[0117] For purposes of the present disclosure, certain aspects, advantages, and novel features are described herein. Not all of these advantages may be achieved according to any particular embodiment. Thus, for example, one skilled in the art will recognize that the present disclosure may be implemented or performed in a manner that achieves one advantage or a group of advantages taught herein without necessarily achieving other advantages that may be taught or suggested herein.

[0118] Unless otherwise specifically stated or understood in the context of use, conditional language used herein, such as "can", "could", "might", "may", "for example", etc., is generally intended to express that certain embodiments include, while certain embodiments do not include certain features, elements and / or steps. Therefore, such conditional language is generally not intended to imply that features, elements and / or steps are in any way necessary for one or more embodiments, or that one or more embodiments necessarily include logic for determining that these features, elements and / or steps are included or will be performed in any particular embodiment with or without other input or prompting. The terms "comprising", "including", "having", etc. are synonymous and are used inclusively in an open-ended manner and do not exclude additional elements, features, actions, operations, etc. In addition, the term "or" is used in its inclusive sense (rather than in its exclusive sense), so that when used, for example, to connect a series of elements, the term "or" means one, some or all of the elements in the list.

[0119] Unless expressly stated otherwise, linking language such as the phrase "at least one of X, Y, and Z" should be understood in light of the context in which it is used, generally expressing that an item, term, etc. may be X, Y, or Z. Thus, such linking language is generally not intended to imply that certain embodiments require the presence of at least one X, at least one Y, and at least one Z.

[0120] The degree language used herein, such as the terms "approximately," "about," "generally," and "substantially" as used herein, refers to a value, amount, or feature that is close to a stated value, amount, or feature that still performs a desired function or achieves a desired result. For example, the terms "approximately," "about," "generally," and "substantially" may refer to an amount that is less than 10%, less than 5%, less than 1%, less than 0.1%, and less than 0.01% of the stated amount. As another example, in certain embodiments, the terms "generally parallel" and "substantially parallel" refer to a value, amount, or feature that deviates from exact parallelism by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, 0.1 degrees, or the opposite.

[0121] Any method disclosed herein does not need to be performed in the order described. The methods disclosed herein include certain actions taken by a practitioner; however, they may also include instructions of any third party for these actions, whether explicit or implicit. For example, an action such as "controlling motor speed" includes "instructing to control motor speed".

[0122] All methods and tasks described herein can be performed by a computer system and fully automated. In some cases, a computer system may include a plurality of different computers or computing devices (e.g., physical servers, workstations, storage arrays, cloud computing resources, etc.), which communicate and interact on a network to perform the functions described. Each such computing device typically includes a processor (or multiple processors) that executes program instructions or modules stored in a memory or other non-temporary computer-readable storage medium or device (e.g., a solid-state storage device, a disk drive, etc.). Various functions disclosed herein may be embodied in such program instructions, and / or may be implemented in a dedicated circuit (e.g., ASICs or FPGAs) of a computer system. In the case where a computer system includes a plurality of computing devices, these devices may be but need not be collocated. The results of the disclosed methods and tasks may be persistently stored by converting physical storage devices such as solid-state storage chips and / or disks into different states. In some embodiments, a computer system may be a cloud-based computing system whose processing resources are shared by a plurality of different business entities or other users.

[0123] The scope of the present disclosure is not intended to be limited by the specific disclosure of preferred embodiments in this section or elsewhere in this specification, and may be limited by the claims as in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims, and not limited to the examples described in this specification or during the prosecution of the application, which examples should be interpreted as non-exclusive.

Claims

1. An electrophysiological cardiac ablation system, comprising: a first generator configured to generate a non-ablative blocking current; a second generator configured to generate an ablative energy modality; An integrated catheter, wherein the integrated catheter has a proximal end and a distal end, the proximal end being configured to couple with the first generator and the second generator, and wherein the integrated catheter further comprises: a conductor extending from a proximal end of the integrated catheter to a distal end of the integrated catheter, wherein the conductor is disposed within the integrated catheter; and at least one occluding electrode disposed at a distal region of the integrated catheter and configured to be in conductive connection with the first generator; at least one ablation electrode disposed at a distal region of the integrated catheter and configured to be conductively connected to the second generator; wherein the system is configured to produce a reversible blockage in cardiac tissue by delivering the blocking current from the first generator to the cardiac tissue via the at least one blocking electrode; and wherein the system is configured to ablate cardiac tissue by delivering the ablative energy modality from the second generator to the at least one ablation electrode, wherein the distal end of the integrated catheter has an opening exposing at least one occluding electrode disposed on the integrated catheter, and Wherein the at least one ablation electrode encompasses a circumference of a portion of the distal end of the integrated catheter.

2. The electrophysiological cardiac ablation system of claim 1, wherein the at least one occluding electrode comprises a high charge density material.

3. The electrophysiological cardiac ablation system of claim 1, wherein the at least one occluding electrode is made of silver and / or silver chloride.

4. The electrophysiological cardiac ablation system of claim 1, wherein the first generator is configured to generate non-ablative DC or HFAC.

5. The electrophysiological cardiac ablation system of claim 1, wherein the conductor comprises a wire.

6. The electrophysiological cardiac ablation system of claim 1, wherein the at least one occluding electrode is configured to sense cardiac tissue activity.

7. The electrophysiological cardiac ablation system of claim 1, wherein the at least one ablation electrode is an RF ablation electrode.

8. The electrophysiological cardiac ablation system of claim 1, wherein the integrated catheter is flexible enough to allow contact between the at least one occluding electrode and the cardiac tissue.

9. The electrophysiological cardiac ablation system of claim 1, wherein the at least one occluding electrode is disposed on a balloon positioned proximate a distal end of the integrated catheter, and wherein the balloon is configured to be inflated such that the at least one occluding electrode is able to directly contact cardiac tissue.

10. An integrated catheter comprising: a proximal end configured to be coupled to a generator; remote; at least one occlusion electrode disposed proximate a distal end of the integrated catheter and configured to be in conductive connection with the generator; at least one ablation electrode disposed proximate a distal end of the integrated catheter and configured to be in conductive connection with the generator; wherein the integrated catheter is configured to occlude cardiac tissue by delivering an occluding current from the generator to the cardiac tissue via the at least one occluding electrode; and wherein the integrated catheter is configured to ablate cardiac tissue by delivering electrical current from the generator to the at least one ablation electrode, wherein the distal end of the integrated catheter has an opening exposing at least one occluding electrode disposed on the integrated catheter, and Wherein the at least one ablation electrode encompasses a circumference of a portion of the distal end of the integrated catheter.

11. The integrated catheter of claim 10, wherein at least one of the electrodes is configured to sense cardiac tissue activity.

Citation Information

Patent Citations

  • Therapy delivery devices and methods for non-damaging neural tissue conduction block

    US10071241B2

  • Systems and methods for direct current nerve conduction block

    US20180280691A1

  • Separated-interface nerve electrode

    US9008800B2

  • Catheter With Irrigated Tip Electrode With Porous Substrate And High Density Surface Micro-Electrodes

    CN105726118A

  • Controlled tissue ablation techniques

    CN106659531A